Baebies Announces Assays for FINDER Launch Panel: G6PD, Total Serum Bilirubin, Albumin and Direct Bilirubin
Baebies, Inc., a company focused on advancing newborn screening and pediatric testing, announced the first assays on the FINDER launch panel, currently under development. The panel includes tests for total serum bilirubin, albumin, direct bilirubin, and glucose-6-phosphate dehydrogenase (G6PD) on a single cartridge, making it the first comprehensive, rapid and near-patient testing solution for hyperbilirubinemia.
Durham, NC, July 31, 2017 --(PR.com)-- Experience a hands-on demonstration of FINDERTM at Booth 855 during AACC 2017.
Baebies, Inc., a company focused on advancing newborn screening and pediatric testing, announced the first assays on the FINDER launch panel, currently under development. The panel includes tests for total serum bilirubin, albumin, direct bilirubin, and glucose-6-phosphate dehydrogenase (G6PD) on a single cartridge, making it the first comprehensive, rapid and near-patient testing solution for hyperbilirubinemia. A robust pipeline of future panels for other disorders using the same cartridge on FINDER is also in development.
Hyperbilirubinemia is a condition in which bilirubin levels in the blood are elevated and the newborn becomes jaundiced. When unmonitored or untreated, neonatal jaundice can lead to severe neurotoxicity, including kernicterus and other associated morbidities.
There is currently a gap in point of care testing devices for G6PD, a deficiency that leads to hyperbilirubinemia and approximately 21% of kernicterus cases. The FINDER launch panel will address a critical need for G6PD testing and brings together the most common analytes used to assess hyperbilirubinemia. Each test on the FINDER launch panel contributes to a more complete understanding of why jaundice develops in a newborn. Rapid access to these measurements may allow clinicians to treat severe neonatal hyperbilirubinemia faster and more effectively, thereby preventing irreversible neurological damage.
“Our neonates have very limited volume of blood available for the many tests and technologies required for current hyperbilirubinemia standard of care. Identifying newborns at-risk for hyperbilirubinemia using a single drop of blood on FINDER not only reduces the amount of pain a neonate must endure, but also reduces the time to provide physicians with important information that will direct care,” says Dr. Michael Cotten, Director of Neonatology Clinical Research at Duke University School of Medicine.
FINDER is the only platform specifically designed to address the unique needs of neonatal testing. FINDER substantially decreases both sample size and testing time, enables testing in the nursery or anywhere in the hospital, and delivers comprehensive test panels – even across multiple test types – to solve acute problems in neonatology. Simple operations and test flexibility enable FINDER to provide results in minutes. A hands-on demonstration of FINDER will be held at Booth 855 during the AACC Annual Scientific Meeting & Clinical Lab Expo in San Diego, California from August 1-3, 2017.
About Baebies, Inc.
At Baebies our sole focus is to advance newborn screening and other pediatric testing worldwide. Baebies is guided by the vision that “everyone deserves a healthy start.” Baebies delivers innovative products and services to make life better for millions of babies. By bringing new technologies and new tests to the healthcare community, Baebies is providing hope to parents and the chance at a better life to newborns. FINDER is not available at this time for sale or use in any territory. For more information visit www.baebies.com.
Contact:
Jessica Kettler
Jkettler@baebies.com
919-328-8332
Baebies, Inc., a company focused on advancing newborn screening and pediatric testing, announced the first assays on the FINDER launch panel, currently under development. The panel includes tests for total serum bilirubin, albumin, direct bilirubin, and glucose-6-phosphate dehydrogenase (G6PD) on a single cartridge, making it the first comprehensive, rapid and near-patient testing solution for hyperbilirubinemia. A robust pipeline of future panels for other disorders using the same cartridge on FINDER is also in development.
Hyperbilirubinemia is a condition in which bilirubin levels in the blood are elevated and the newborn becomes jaundiced. When unmonitored or untreated, neonatal jaundice can lead to severe neurotoxicity, including kernicterus and other associated morbidities.
There is currently a gap in point of care testing devices for G6PD, a deficiency that leads to hyperbilirubinemia and approximately 21% of kernicterus cases. The FINDER launch panel will address a critical need for G6PD testing and brings together the most common analytes used to assess hyperbilirubinemia. Each test on the FINDER launch panel contributes to a more complete understanding of why jaundice develops in a newborn. Rapid access to these measurements may allow clinicians to treat severe neonatal hyperbilirubinemia faster and more effectively, thereby preventing irreversible neurological damage.
“Our neonates have very limited volume of blood available for the many tests and technologies required for current hyperbilirubinemia standard of care. Identifying newborns at-risk for hyperbilirubinemia using a single drop of blood on FINDER not only reduces the amount of pain a neonate must endure, but also reduces the time to provide physicians with important information that will direct care,” says Dr. Michael Cotten, Director of Neonatology Clinical Research at Duke University School of Medicine.
FINDER is the only platform specifically designed to address the unique needs of neonatal testing. FINDER substantially decreases both sample size and testing time, enables testing in the nursery or anywhere in the hospital, and delivers comprehensive test panels – even across multiple test types – to solve acute problems in neonatology. Simple operations and test flexibility enable FINDER to provide results in minutes. A hands-on demonstration of FINDER will be held at Booth 855 during the AACC Annual Scientific Meeting & Clinical Lab Expo in San Diego, California from August 1-3, 2017.
About Baebies, Inc.
At Baebies our sole focus is to advance newborn screening and other pediatric testing worldwide. Baebies is guided by the vision that “everyone deserves a healthy start.” Baebies delivers innovative products and services to make life better for millions of babies. By bringing new technologies and new tests to the healthcare community, Baebies is providing hope to parents and the chance at a better life to newborns. FINDER is not available at this time for sale or use in any territory. For more information visit www.baebies.com.
Contact:
Jessica Kettler
Jkettler@baebies.com
919-328-8332
Contact
Baebies
Jessica Kettler
919-328-8332
www.baebies.com
Jessica Kettler
919-328-8332
www.baebies.com
Contact
Categories